In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs. In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies / S. Pusceddu, F. De Braud, G. Lo Russo, L. Concas, D. Femia, C. Vernieri, A. Indini, B. Formisano, R. Buzzoni. - In: ONCOTARGET. - ISSN 1949-2553. - 7:28(2016 Apr), pp. 44841-44847.
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
S. PuscedduPrimo
;F. De BraudSecondo
;C. Vernieri;A. Indini;
2016
Abstract
In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs. In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.
| File | Dimensione | Formato | |
|---|---|---|---|
|
8601-130613-3-PB.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
704.05 kB
Formato
Adobe PDF
|
704.05 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
